B. Riley Wealth Advisors Inc. Has $392,000 Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

B. Riley Wealth Advisors Inc. decreased its position in Grifols, S.A. (NASDAQ:GRFS) by 22.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 44,018 shares of the biotechnology company’s stock after selling 12,932 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Grifols were worth $392,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in GRFS. Brandes Investment Partners LP grew its stake in Grifols by 8.7% in the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock valued at $117,242,000 after acquiring an additional 1,481,924 shares during the period. Black Creek Investment Management Inc. lifted its holdings in shares of Grifols by 7.7% during the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after purchasing an additional 881,155 shares in the last quarter. Armistice Capital LLC grew its position in shares of Grifols by 18.7% in the 2nd quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock valued at $49,759,000 after purchasing an additional 1,244,000 shares during the period. Whitebox Advisors LLC increased its stake in Grifols by 56.2% during the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock worth $37,487,000 after purchasing an additional 1,519,093 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in Grifols by 4.7% during the 2nd quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock worth $13,931,000 after buying an additional 100,131 shares during the period.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $7.51 on Friday. The company has a fifty day moving average price of $8.37 and a 200 day moving average price of $8.10. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15. The firm has a market cap of $5.16 billion, a PE ratio of 7.74 and a beta of 0.43. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.